FDA Peptide Reclassification 2026: BPC-157 and 13 Others Set to Return to Compounding Pharmacies
HHS Secretary Robert F. Kennedy Jr. announced in February 2026 that approximately 14 peptides previously restricted from compounding would be moved back to Category 1 status, restoring legal prescriber access — with BPC-157 among the most anticipated names on the list.
Source: AgeMD
FDA Approves Innovative Peptide Therapy for Alzheimer’s Disease
The FDA has granted approval for a new peptide-based therapy aimed at slowing the progression of Alzheimer’s disease, marking a significant milestone in neurodegenerative treatment.
Source: ThePBrief Research
FDA Approves Novel Peptide Drug Targeting Rare Genetic Disorder
The FDA recently granted accelerated approval to a new peptide therapy designed to treat the rare genetic disorder Alkaptonuria, offering hope to affected patients.
Source: ThePBrief Research
FDA Greenlights Tirzepatide for Obesity Treatment: A Major Milestone
The FDA has approved tirzepatide for chronic weight management, marking a significant advancement in peptide therapies for obesity. This decision opens new avenues for treatment options.
Source: ThePBrief Research
FDA Prepares New Guidelines for Peptide Drug Approvals
The FDA is set to release new guidelines aimed at streamlining the approval process for peptide-based therapeutics, reflecting the growing importance of peptides in modern medicine.
Source: ThePBrief Research
FDA Approves New Peptide Therapy for Opioid Addiction
The FDA has granted approval for a novel peptide treatment aimed at addressing opioid addiction, marking a landmark achievement in addiction therapy.
Source: ThePBrief Research
FDA Approves Innovative Peptide Therapeutic for Alzheimer’s Disease
The FDA has granted approval for a new peptide-based therapy aimed at slowing the progression of Alzheimer’s disease, signaling a promising advancement in neurodegenerative treatments.
Source: ThePBrief Research
Medicare to Launch GLP-1 Coverage Demonstration Program in July 2026
CMS announces a new payment demonstration that will provide Medicare beneficiaries with access to GLP-1 medications for obesity, bridging to the full BALANCE Model in 2027.
Source: CMS.gov
14 Peptides Including BPC-157 and TB-500 Reclassified Back to Legal Compounding Status
HHS Secretary Kennedy announces that 14 previously restricted peptides will return to Category 1, restoring access through compounding pharmacies with a prescription.
Source: Peptibase
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.